Compounds for sight restoration

PCT/EP2024/064381Blindness greatly affects human life and personal destinies. In adults, visual impairment causes loss of personal independence and the ability to work in many cases, often leading to the need for disability pensions, social services, and nursing. Around 3 million Europeans suffer from low vision and almost 700,000 have been legally recognized as blind. There are several inherited and acquired forms of blindness, including retinal degenerative diseases such as retinitis pigmentosa, in which photoreceptor cells are progressively lost, leading to visual impairment with very limited treatment options. More common degenerative diseases are age-related macular degeneration (AMD), Leber's congenital amaurosis, Usher syndrome, S-linked juvenile retinoschisis, and Stargardt disease.The present invention relates to compounds which are photoswitchable modulators of the mGlu6 receptor, pharmaceutical compositions comprising said compounds, and to the use of said compounds and pharmaceutical compositions as a medicament, in particular for the treatment and/or prevention of retinitis pigmentosa, and/or for the enhancement of visual performance in healthy subjects.